Abstract
The article was well written, clear and relevant to the challenges facing the clinical research industry. Missing data points threaten the validity of many clinical trials. At the request of the Food and Drug Administration (FDA) and with its funding, the panel on the handling of missing data in clinical trials was created by the National Research Council's (NRC) Committee on National Statistics. This panel published a report with recommendations that was intended to be used by the FDA for guidance on handling missing data for the entire clinical trial community so that the latter can take measures to improve the conduct and analysis of clinical trials. The current article provides an overview of the findings and recommendations of the resultant report from the perspective of one member of the NRC panel. Overall the paper succinctly summarizes issues related to missing data and the current state of challenges pertaining to the topic. It creates an understanding of the topic for the reader by discussing some of the main recommendations from the NRC panel’s report on this topic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
